Home › Myasthenia Gravis › Michigan
Myasthenia Gravis clinical trials in Michigan
11 studies for Myasthenia Gravis are looking for participants at sites in Michigan.
Cities in Michigan
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1026, Detroit
- Site Number - 1005, East Lansing
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Nov 13, 2026 · NCT07039916A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
- C.S. Mott Children's Hospital, Ann Arbor
RecruitingPhase 2/3
Ages 2 to 17 · All sexes · Updated Nov 4, 2026 · NCT05265273Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Henry Ford Hospital, Detroit
- Michigan State University, East Lansing
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Nov 3, 2026 · NCT07217587A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
- TG Therapeutics Investigational Trial Site, Farmington Hills
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07673744A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, Ann Arbor
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06680037ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Henry Ford Health System, Detroit
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07294170Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases
- Karmanos Cancer Institute, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06626919ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Henry Ford Health Systems, Detroit
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07284420Study of Aritinercept in Patients With Generalized Myasthenia Gravis
- Aurinia Investigational Site, Dearborn
- Aurinia Investigational Site, Flint
RecruitingPhase 1/2
Ages 18 to 85 · All sexes · Updated Aug 3, 2026 · NCT07596901Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, Lansing
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 18, 2026 · NCT04202341A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
- Henry Ford Health System, Detroit
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 17, 2026 · NCT06298565From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.